Abstract:We read with interest the article by Rossetti et al. reviewing the phenotypic spectrum associated with haploinsufficiency of MYRF (Rossetti et al., 2019). The authors identified three novel mutations in three patients with cardiac–urogenital–diaphragm–lung (CUDL) disorders. They further reviewed the phenotypic spectrum involving CUDL disorders based on 16 reported patients with mutations in MYRF. However, three recently published papers (Garnai et al., 2019; Guo et al., 2019; Xiao et al., 2019) independently identified that novel truncation mutations in MYRF are responsible for a spectrum of disorders related to autosomal dominant high hyperopia (adHH) (Nowilaty et al., 2013). These findings are of great interest because primary angle closure glaucoma (PACG), one of the most common forms of glaucoma in East Asians (Sun et al., 2017), is frequently accompanied with MYRF-associated high hyperopia (Garnai et al., 2019; Othman et al., 1998; Xiao et al., 2019). PACG or occludable anterior chamber angles, present in 12 of the 22 individuals with high hyperopia in one family (Othman et al., 1998), were caused by a MYRF mutation. PACG was also present in two families with high hyperopia caused by MYRF mutations (Xiao et al., 2019). Therefore, the phenotypic spectrum by truncation mutations in MYRF includes not only CUDL spectrum but also adHH and PACG. Mutations in genes, including MYRF and many others, that contribute to the development of eye size and structure (Sun et al., 2019), are important genetic factors in the development of PACG, although not all of these genes are associated with PACG. In addition, MYRF is the first such gene responsible for autosomal dominant PACG, and further investigation into the pathogenesis of MYRF mutations may shed light on the molecular mechanism of PACG. So far, it seems that patients with adHH usually have truncation mutations in the C-terminal region of MYRF while patients with CUDL disorders usually have mutations in the N-terminal or central portion. Neither high hyperopia nor PACG have been reported in patients with CUDL disorders caused by MYRF mutations (Rossetti et al., 2019). However, ocular phenotypes cannot be excluded in these patients because one patient with an N-terminal truncation mutation was reported to have adHH accompanied with systemic phenotypes which was consistent with CUDL disorders at the age of 8 years old (Garnai et al., 2019). The reason that neither adHH nor PACG were mentioned in other patients with MYRF-related CUDL disorders might be that they were obscured by CUDL disorders that were at the severe end of the spectrum. In addition, CUDL is not mentioned in most patients with adHH caused by MYRF mutations (Garnai et al., 2019; Othman et al., 1998; Xiao et al., 2019). It would be interesting to know whether the various phenotypes are solely contributed by mutations at different portion of the MYRF or whether the severity of ocular or nonocular signs may correlate with the location of a truncated mutation in MYRF. To clarify this point, it would be helpful if the eyes, heart, genitourinary tract, diaphragm, and lungs were systemically checked in cases with mutations in MYRF reported in future studies. MYRF encodes a transcription factor that is critical for oligodendrocyte differentiation and central nervous system myelination. MYRF is a membrane-bound protein in the endoplasmic reticulum in which the N-terminal fragment is self-cleaved and then translocated into the nucleus to activate expression of myelin gene, while the C-terminal portion is retained without a known function (Bujalka et al., 2013; Huang et al., 2018; Kim et al., 2017). Further study is also expected to explore the functional role of the C-terminal portion of MYRF, especially the pathogenesis underlying high hyperopia and PACG.

MYRF: A New Regulator of Cardiac and Early Gonadal Development-Insights from Single Cell RNA Sequencing Analysis

Case Report: De Novo Variant in Myelin Regulatory Factor in a Chinese Child with 46,XY Disorder/difference of Sex Development, Cardiac and Urogenital Anomalies, and Short Stature

Myelin regulatory factor ( Myrf ) is a critical early regulator of retinal pigment epithelial development

( ) is a critical early regulator of retinal pigment epithelial development

Heterozygous variants disrupting the interaction of ERF with activated ERK1/2 cause microcephaly, developmental delay, and skeletal anomalies

Fetal Presentation of MYRF‐Related Cardiac Urogenital Syndrome: An Emerging and Challenging Prenatal Diagnosis

MYRF: A unique transmembrane transcription factor‐ from proteolytic self‐processing to its multifaceted roles in animal development

Analysis of MYRF gene variant in a fetus with Cardiac-urogenital syndrome

Correspondence to Rossetti Et Al.'s Review of the Phenotypic Spectrum Associated with Haploinsufficiency of MYRF

Loss-of-function variants in ERF are associated with a Noonan syndrome-like phenotype with or without craniosynostosis

Myelin Regulatory Factor Deficiency is Associated with the Retinal Photoreceptor Defects in Mice.

Loss-of-function of RNA-binding protein PRRC2B causes translational defects and congenital cardiovascular malformation

Novel Mutations of the SRF Gene in Chinese Sporadic Conotruncal Heart Defect Patients

Abstract 658: RNF20/40 Regulates Cardiomyocyte Maturation

Hierarchical and Stage-Specific Regulation of Murine Cardiomyocyte Maturation by Serum Response Factor.

Etiology of Craniofacial and Cardiac Malformations in a Mouse Model of SF3B4-Related Syndromes

Sex-specific single cell-level transcriptomic signatures of Rett syndrome disease progression

Increased Expression of Bypasses to Drive 46,XX Testicular Development: A New Mechanism of 46,XX DSD

Identification Of Novel Single-Nucleotide Variants With Potential Of Mediating Malfunction Of Microrna In Congenital Heart Disease